J Korean Androl Soc.  1994 Dec;12(2):149-153.

Placebo-Controlled Double-Blind Study of Terazocin for Treatment of Benign Prostatic Hyperplasia

• Kal WJ
• Moon YT
• Kim SC

Abstract

The rationale for using alpha-blockade to treat benign prostatic hyperplasia(BPH) arises from the physiology and pharmacology of prostatic smooth muscle. Approximately 20% of the area density of prostate adenoma is smooth muscle ; alpha blockers presumably can decrease the resistance along the prostatic urethra by relaxing this smooth muscle component. The primary advantage of terazocin over all other commercially available alpha-blockers is that its longer half-life allows for a once-daily dosage regimen. In a placebo-controlled double-blind study, 20 patients with symptomatic BPH were assigned to take 2-4mg of terazocin at bedtime for 5 months. The peak urinary flow rate increased an average of 31%, and the mean flow rate increased an average of 24% in these men. The symptom scores improved 40%. The adverse reactions were orthostatic hypotension and general weakness(1 case) in the terazocin group and general weakness(1 case) in the placebo group. In summary, terazocin administered once a day reduced the obstructive and irritative symptoms of BPH and improved urine flow rates. The drug was well tolerated.

MeSH Terms

Adenoma
Double-Blind Method*
Half-Life
Humans
Hypotension, Orthostatic
Male
Muscle, Smooth
Pharmacology
Physiology
Prostate
Prostatic Hyperplasia*
Urethra